AbbVie raised its full-year adjusted earnings guidance to $14.08-$14.28 per share, surpassing Wall Street’s $14.12/share estimate. First-quarter revenue hit $15 billion, a 12% increase driven by strong performance in immunology and neuroscience divisions. The immunology portfolio grew 16%, with arthritis drug Skyrizi up 31% and Crohn’s treatment Rinvoq rising 23%.

However, legacy drug Humira fell 39% year-over-year as generic competitors erode its market share.Neuroscience revenue surged 26%, reflecting demand for Alzheimer’s and Parkinson’s therapies. Analysts note the guidance hike signals confidence in AbbVie’s pipeline, though reliance on aging blockbusters like Humira remains a risk. The move aligns with broader sector trends toward specialty care, but execution on cost-cutting and innovation will determine long-term success.